Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

NanoViricides, Inc. Common Stock (NY:NNVC)

1.485 +0.085 (+6.07%)
Delayed Quote Updated: 11:15 AM EDT, Oct 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 164,687
Open 1.430
Bid (Size) 1.480 (300)
Ask (Size) 1.490 (4,700)
Prev. Close 1.400
Today's Range 1.400 - 1.500
52wk Range 0.8500 - 2.230
Shares Outstanding 15,641,611
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) to Present at NIBA 153rd Investment Conference
Via Investor Brand Network
Topics Intellectual Property
News headline image
NanoViricides Presenting at NIBA's 153rd Investment Conference in Fort Lauderdale, FL October 7, 2026
From NanoViricides
Via ACCESS Newswire

Performance

52-Week Range 33.4% below 52-week high
1.485
0.8552W Low 2.2352W High
1 Week 1.0% below 1-week high
1.231W Low 1.501W High

NanoViricides, Inc. Common Stock (NNVC) traded between $0.85 and $2.23 over the past 52 weeks and last traded at $1.49, 33.4% below its 52-week high. Over the past week it ranged between $1.23 and $1.50.

Past 12 Months
+14.2%
+37.5%
+1.0%
+37.5%
+22.7%
+2.4%
1W +$0.19
1M +$0.41
3M +$0.02
6M +$0.41
YTD +$0.28
1Y +$0.04

NNVC was +2.4% over the past year, +37.5% over six months, +22.7% year to date, +14.2% in the last week.

12 Months vs Market
NNVC
+2.4%
DIA
+9.1%
SPY
+15.4%
QQQ
+24.3%
IWM
+12.4%

Over the past 12 months NNVC returned +2.4% versus DIA (Dow) +9.1%, SPY (S&P 500) +15.4%, QQQ (Nasdaq 100) +24.3% and IWM (Russell 2000) +12.4%.

Volume & Liquidity 0.37× 3-mo avg
Today 164,687 3-mo avg 447.9K
1W
376.5K
1M
668.6K
3M
447.9K
6M
674.4K
YTD
536.3K
1Y
491.1K

NNVC most recently traded 164,687 shares against a 3-month average daily volume of 447.9K.

More News

Read More
BioMedNewsBreaks – NanoViricides (NYSE American: NNVC) Provides Update on Phase II Ebola Trial of NV-387 Oral Gummies
Via Investor Brand Network
Topics Intellectual Property
News headline image
NanoViricides Provides Additional Details on the Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola as the Outbreak Continues to Expand and Has Taken Over 4,000 Lives
From NanoViricides
Via ACCESS Newswire
MissionIRNewsBreaks – NanoViricides (NYSE American: NNVC) Reports Fiscal 2026 Results, Advances NV-387 Phase II Trials
Via Investor Brand Network
Topics Intellectual Property
News headline image
NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Is In Phase II Clinical Trials
From NanoViricides
Via ACCESS Newswire
MissionIRNewsBreaks – NanoViricides (NYSE American: NNVC) Begins Patient Enrollment and Dosing in Phase II NV-387 Ebola Trial
Via Investor Brand Network
Topics Intellectual Property
News headline image
Clinical Trial of the Oral Drug NV-387 to Treat Ebola Has Started Enrollment and Dosing of Patients Last Week (on or about September 23rd), Says NanoViricides
From NanoViricides
Via ACCESS Newswire
News headline image
Phase II Clinical Trial of NV-387 as a Treatment for Monkeypox (MPox) Has Begun in DRC, Announces NanoViricides
From NanoViricides
Via ACCESS Newswire
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Phase II Ebola Trial of NV-387 Oral Gummies Set to Begin Next Week in DRC
Via Investor Brand Network
Topics Intellectual Property
News headline image
Clinical Trial of the Oral Drug NV-387 to Treat Ebola to Start Next Week, Hoping to Reduce Fatalities and Spread, As the Largest Ebola Outbreak is Expanding in 
DR Congo with 48% Crude Fatality Rate, Says NanoViricides
From NanoViricides
Via ACCESS Newswire
News headline image
A $57 Billion Antiviral Market Is Taking Shape As The World Prepares For The Next Viral Threat
Via FinancialNewsMedia
News headline image
A $57 Billion Antiviral Market Is Taking Shape As The World Prepares For The Next Viral Threat
From MarketNewsUpdates.com
Via GlobeNewswire
NetworkNewsBreaks – NanoViricides (NYSE American: NNVC) Registers Phase II Ebola Trial for NV-387 Oral Gummies
Via Investor Brand Network
Topics Intellectual Property
News headline image
Clinical Trial for an Oral Drug to Treat Ebola is Registered in the Pan African Clinical Trials Database and is Ready to Go, As the Largest Ebola Outbreak Continues to Expand in DR Congo
From NanoViricides
Via ACCESS Newswire
BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) Advances NV-387 Measles Treatment Program Toward Phase II Trial
Via Investor Brand Network
Topics Intellectual Property
News headline image
While Measles Cases Continue to Increase in The USA and Globally, NanoViricides is Getting Ready for Clinical Trials of Its Revolutionary Broad-spectrum Drug Candidate NV-387 as A Treatment for Measles
From NanoViricides
Via ACCESS Newswire
MissionIRNewsBreaks – NanoViricides (NYSE American: NNVC) Expects Phase II Ebola Trial of NV-387 Oral Gummies to Begin Soon in DRC
Via Investor Brand Network
Topics Intellectual Property
News headline image
The Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo to Fight the Current Largest Ever and Expanding Ebola Outbreak to Begin Soon
From NanoViricides
Via ACCESS Newswire
BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) Receives Regulatory Approval for Phase II Ebola Trial of NV-387 Oral Gummies
Via Investor Brand Network
Topics Death Intellectual Property
News headline image
NanoViricides Has Received Regulatory Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo To Fight the Current Largest Ever and Expanding Ebola Outbreak
From NanoViricides
Via ACCESS Newswire
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Awaits Regulatory Decision on Ebola Trial for NV-387 Oral Gummies
Via Investor Brand Network
Topics Intellectual Property
News headline image
NanoViricides Awaits Approval from DR Congo Regulatory Agency for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola, Financing Completed to Support the Trial
From NanoViricides
Via ACCESS Newswire
NetworkNewsBreaks – NanoViricides (NYSE American: NNVC) Announces Approximately $3.8 Million Registered Direct Offering
Via Investor Brand Network
Topics Intellectual Property
News headline image
NanoViricides Announces Pricing of ~$3.8 Million Registered Direct Offering
From NanoViricides
Via ACCESS Newswire

Frequently Asked Questions

Is NanoViricides, Inc. Common Stock publicly traded?
Yes, NanoViricides, Inc. Common Stock is publicly traded.
What exchange does NanoViricides, Inc. Common Stock trade on?
NanoViricides, Inc. Common Stock trades on the New York Stock Exchange
What is the ticker symbol for NanoViricides, Inc. Common Stock?
The ticker symbol for NanoViricides, Inc. Common Stock is NNVC on the New York Stock Exchange
What is the current price of NanoViricides, Inc. Common Stock?
The current price of NanoViricides, Inc. Common Stock is 1.485
When was NanoViricides, Inc. Common Stock last traded?
The last trade of NanoViricides, Inc. Common Stock was at 10/07/26 11:15 AM ET
What is the market capitalization of NanoViricides, Inc. Common Stock?
The market capitalization of NanoViricides, Inc. Common Stock is 23.23M
How many shares of NanoViricides, Inc. Common Stock are outstanding?
NanoViricides, Inc. Common Stock has 23M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.